Arcellx Inc at iMMagine-1 Pivotal Study Results EHA2025 Transcript - Thomson StreetEvents

Arcellx Inc at iMMagine-1 Pivotal Study Results EHA2025 Transcript

Arcellx Inc at iMMagine-1 Pivotal Study Results EHA2025 Transcript - Thomson StreetEvents
Arcellx Inc at iMMagine-1 Pivotal Study Results EHA2025 Transcript
Published Jun 13, 2025
25 pages (18943 words) — Published Jun 13, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ACLX.OQ corporate analyst meeting

  
Brief Excerpt:

...Good evening, I'm Rami Elghandour, I'm the Chairman and CEO of Arcellx, and it is my privilege to welcome you to our Investor Relations event here in Milan. Thank you so much for those who joined us in person, you get extra credit and thanks as well for many of you joining via our webcast. Before we get started, a look at our forward-looking statements. In terms of our program for this evening, I'm going to kick things off by sharing a little bit more about why we're building a different kind of cell therapy company. I then have the pleasure of welcoming Dr. Kaur to the stage. She'll share the latest results from our registrational iMMagine-1 study that has been selected for an oral abstract presentation here at EHA that she herself will be presenting tomorrow at 5:00 PM. Dr. Chris Heery, our Chief Medical Officer, will then share -- lead a physician panel and he'll be joined by both Dr. Kaur as well as Dr. Patel. Dr. Kaur joins us from Mount Sinai and Dr. Patel from MD Anderson, and we're...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Arcellx Inc
Ticker
ACLX.OQ
Time
6:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: John Newman - Canaccord Genuity LLC - Analyst : Great. John Newman from Canaccord. Thank you to the physicians as well as. So I think Dr. Kaur, you mentioned something that I actually heard from another group at ASCO about pulling talquetamab forward and using it as bridging. My question is, when you have some of the CAR-Ts that require a very long manufacturing time, -does that require you to pull therapies forward into bridging and ultimately use them longer than you normally would such that maybe later on, there may be not quite as attractive? I'm just curious about how you think about that.

Table Of Contents

Arcellx Inc to Host Investor Relations Event Transcript – 2025-12-07 – US$ 54.00 – Edited Transcript of ACLX.OQ corporate analyst meeting</ 7-Dec-25 1:00am GMT

Arcellx Inc at Morgan Stanley Global Healthcare Conference Transcript – 2025-09-10 – US$ 54.00 – Edited Transcript of ACLX.OQ presentation 10-Sep-25 5:05pm GMT

Arcellx Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript – 2025-05-27 – US$ 54.00 – Edited Transcript of ACLX.OQ presentation 27-May-25 4:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Arcellx Inc at iMMagine-1 Pivotal Study Results EHA2025 Transcript" Jun 13, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Arcellx-Inc-at-iMMagine-1-Pivotal-Study-Results-EHA2025-T16386915>
  
APA:
Thomson StreetEvents. (2025). Arcellx Inc at iMMagine-1 Pivotal Study Results EHA2025 Transcript Jun 13, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Arcellx-Inc-at-iMMagine-1-Pivotal-Study-Results-EHA2025-T16386915>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.